Abu Dhabi’s (DoH) Policy on Assisted Reproductive Services

By Staff Writer

February 17, 2023

Understanding THIQA’s Policy on Assisted Reproductive Services

THIQA’s policy outlines the eligibility criteria, benefits, and reimbursement packages for Assisted Reproductive Techniques (ART) in Abu Dhabi. It is not a clinical management guideline, but rather a framework to ensure eligible patients in need of ART treatments receive coverage based on evidence-based medical criteria.

Determining Medical Necessity in Assisted Reproductive Treatments

THIQA covers Assisted Reproductive treatments deemed medically necessary. This could be due to a couple trying for pregnancy for at least a year, or one or both individuals diagnosed with infertility problems. Infertility can also be diagnosed prior to one year if there are features or findings indicative of subfertility, such as oligo or amenorrhea, history of pelvic infection, or abnormality in semen parameters.

Eligibility and Covered Services

The preferred age range for women seeking fertility is between 18-47 years. Exceptions apply for fertility preservation in female patients diagnosed with cancer. The Body Mass Index (BMI) eligibility range is from 19-40. Covered services include treatment, oocyte and embryo cryopreservation, transfer of embryos, medications, in vitro fertilisation (IVF), and genetic investigations.

The Future of Assisted Reproductive Services

The policy is a testament to the commitment of THIQA and other life sciences consulting firms to provide value-based healthcare. With advancements in artificial intelligence consulting services, we can expect more personalised and effective treatments in the future.

 

Reference url

Recent Posts

oral cancer East Africa
   

Oral Cancer in East Africa: The Need for Early Detection

💡 Did you know that Toombak use is a leading risk factor for oral cancer in East Africa?

A recent scoping review sheds light on the shocking prevalence of oral cancer in the region, emphasising the urgent need for public health interventions and improved early detection strategies. Enhancing awareness around risk factors like Toombak, tobacco, and alcohol for tackling this growing health crisis.

Curious about the key insights and their implications for health economics? Look into the full article to find out more!

#SyenzaNews #HealthEconomics #Oncology #GlobalHealth

Novartis patent cliff layoffs
     

Engineering Resilience: Mastering Pharma Patent Expiration Strategy

🚨 Are you still reacting to pharmaceutical patent expirations with layoffs and litigation, or are you ready to engineer a strategy that turns the patent cliff into your next competitive edge?

Patent expirations don’t have to derail your pharma portfolio. Learn how to outmaneuver generics and transform challenges into advantages. Dive into our latest insights and take control today.

#SyenzaNews #pharmaceuticals #innovation #PharmaStrategy #patentcliffs

diabetes medicine access
               

Improving Diabetes Medicine Access: Key Changes in the Pharmaceutical Benefits Scheme

🚀 Are we on the verge of a breakthrough in diabetes medication accessibility?

The latest updates to the Pharmaceutical Benefits Scheme (PBS) are set to transform type 2 diabetes management by expanding access to essential medicines like empagliflozin and streamlining the prescribing process for glucagon-like peptide 1 receptor agonists (GLP-1 RAs). These changes not only prioritize equity for high-risk populations but also align with global trends in cost-effective healthcare.

Dive deeper into how these revisions could reshape diabetes care and promote better health outcomes for all.

#SyenzaNews #HealthcareInnovation #healthcare #MarketAccess

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.